Neoadjuvant Tislelizumab + LM-302 + S-1 or Tislelizumab + SOX for CLDN18.2-Positive Gastric/GEJ Adenocarcinoma

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Neoadjuvant Tislelizumab + LM-302 + S-1 or Tislelizumab + SOX for CLDN18.2-Positive Gastric/GEJ Adenocarcinoma	Gastric or Esophagogastric Junction Adenocarcinoma	Recruiting	Phase 2	2026-05-06		NCT07569068

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Ruijin Hospital	454

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Ruijin Hospital Shanghai Jiao Tong University School of Medicine	Shanghai	China	3

Clinical trials